• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Profectus Biosciences

edit

Profectus Biosciences is a research and development company dedicated to harnessing the immune system to treat and prevent viral diseases and cancers through the delivery of our proprietary prime/boost vaccines and small molecules.

Recent Milestones

edit

• 
  Profectus Biosciences received $5.4M in Grant funding. (12/14/11)
  Posted 12/14/11 at 5:29am via finsmes.com
• 
  Profectus Biosciences received $4.4M in Grant funding. (10/6/10)
  Posted 10/12/10 at 6:49pm via dowjones.com
• 
  Profectus Biosciences received $5M in Series C funding. (7/22/09)
  Posted 9/29/09 at 2:21am via bizjournals.com
• 
  Profectus Biosciences received $3M in Venture Round funding. (6/15/07)
  Posted 3/17/10 at 10:02pm via profectusbiosciences.com

Videos

Screenshots

edit

Above: Profectus Biosciences Screenshot -- #1
Uploaded: 9/29/09

Sources

1. Profectus BioSciences, Inc. Announces Additional $3 Million Private Placement of Convertible Notes and Warrants (profectusbiosciences.com) [edit]
2. Profectus Biosciences lands $5M round of venture capital (baltimore.bizjournals.com) [edit]
3. Profectus BioSciences Announces $4.4M In Grants For HIV Vaccine (fis.dowjones.com) [edit]
4. Profectus BioSciences Receives $5.4M Grant (finsmes.com) [edit]